Subunit-selective nucleic acid inhibitors of glutamate receptors
View Patent ↗Inhibitors of AMPA-type glutamate ion channels are useful as biochemical probes for structure-function studies and as drug candidates for a number of neurological disorders and diseases. Disclosed herein is the identification of an RNA inhibitor or aptamer by an in vitro evolution approach and characterization of its mechanism of inhibition on the sites of interaction by equilibrium binding and on the receptor channel-opening rate by a laser-pulse photolysis technique. The aptamer of the invention is a noncompetitive inhibitor of AMPA-type glutamate ion channels, one that selectively inhibits the GluA2Q flip AMPA receptor subunit without any effect on other AMPA receptor subunits or on kainate or NMDA receptors. Furthermore, the aptamer preferentially inhibits the closed-channel state of GluA2Q flip with a K I =1.5 μM or by ˜15-fold over the open-channel state. The potency and selectivity of this aptamer rival those of small molecule inhibitors. Together, these properties make the aptamers of the present invention promising water-soluble, highly potent, GluA2 subunit-selective drugs.
1. An isolated nucleic acid consisting essentially of the nucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 5.
2. The isolated nucleic acid of claim 1 , wherein said nucleic acid binds to a glutamate ion channel receptor.
3. The isolated nucleic acid of claim 2 , wherein said nucleic acid selectively inhibits to a GluA2Q subunit of a glutamate ion channel receptor.
4. The isolated nucleic acid of claim 2 , wherein said nucleic acid selectively binds to a GluA2Q subunit of a closed-channel conformation of a glutamate ion channel receptor.
5. The isolated nucleic acid of claim 2 , wherein said GluA2Q subunit is a GluA2Q flip subunit.
6. The isolated nucleic acid of claim 2 , wherein said glutamate ion channel receptor is an α-amino-3-hydroxyl-5-methyl-4-isoxazole propionic acid (AMPA) receptor.
7. The isolated nucleic acid of claim 1 , wherein said nucleic acid is a non-competitive inhibitor of glutamate ion channel receptor activity.
8. The isolated nucleic acid of claim 1 , wherein the nucleic acid is RNA.
9. A truncated form of the nucleic acid of claim 1 , wherein said isolated nucleic acid contains between 35 and 80 contiguous nucleotides of SEQ ID NO: 1.
10. The isolated nucleic acid of claim 1 , wherein said nucleic acid contains one or more chemically modified nucleotides.
11. The isolated nucleic acid of claim 10 wherein the one or more chemically modified nucleotides has a 2′ fluoro substituent.
12. The isolated nucleic acid of claim 1 , wherein said nucleic acid inhibits glutamate receptor function.
13. The isolated nucleic acid of claim 1 , wherein said nucleic acid has a K 1 of about 1.5 μM.
14. A nucleic acid composition that inhibits an AMPA receptor comprising:
(a) an aptamer consisting essentially of the nucleotide sequence of SEQ ID NO. 1;
(b) an aptamer pair comprising a first aptamer comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4 and a second aptamer comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 5, and SEQ ID NO. 6; or
(c) a combination of (a) and (b).
15. An isolated DNA that encodes an RNA comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6.
16. The isolated DNA of claim 15 wherein the RNA comprises the nucleotide sequence corresponding to SEQ ID NO.: 1.
17. A method of inhibiting a glutamate receptor comprising contacting said receptor with the nucleic acid of claim 1 .
18. A composition comprising the nucleic acid inhibitor of an AMPA receptor of claim 12 and a pharmaceutically acceptable carrier.
19. A method of treating a disease characterized by excessive activation of ionotropic glutamate receptors comprising administering a therapeutically effective amount of a nucleic acid inhibitor of an AMPA receptor of claim 12 .
20. The method of claim 19 , wherein the disease is a neurodegenerative disorder selected from the group consisting of amyotrophic lateral sclerosis, stroke, Alzheimer's disease and Parkinson's syndrome.